PT-141 (Bremelanotide) (5mg)
PT-141 (Bremelanotide) is a melanocortin receptor agonist, MC4R, FDA-approved (Vyleesi®, 2019) for hypoactive sexual desire disorder (HSDD) in premenopausal women. 5mg vial — reconstitute with 1mL of bacteriostatic water for a concentration of 5mg/mL (500mcg per 10 units on a U-100 syringe).
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
PT-141 (Bremelanotide) is a cyclic heptapeptide that acts as a melanocortin receptor agonist at MC4R in the hypothalamus and limbic system. MC4R activation triggers **dopaminergic and oxytocinergic signaling** in the paraventricular nucleus (PVN), enhancing sexual desire. Unlike PDE5 inhibitors (Viagra/Cialis) which act vascularly, PT-141 acts **centrally**, making it effective even in patients unresponsive to PDE5i. Onset is ~45 minutes post-administration, with duration of 6–12 hours.
Quick Start
- Reconstitution: 1.0 mL bacteriostatic water → 5 mg/mL.
- Test Dose: 0.5 mg (10 units) for tolerance assessment.
- Typical Dose: 1–1.75 mg (20–35 units) subcutaneously, 45 minutes prior.
- FDA Limits: ≤1 dose/24h, ≤8 doses/month.
- Storage: 2–8 °C post-reconstitution, use within 28 days.
Dosing Chart — PT-141 5mg (1 mL = 5 mg/mL)
Route: Subcutaneous injection | Frequency: As Needed (PRN)
| Week | Dose | Units (per injection) |
|---|---|---|
| Test | 0.5 mg | 10 Units (0.10 mL) |
| Typical | 1.0 mg | 20 Units (0.20 mL) |
| FDA Max | 1.75 mg | 35 Units (0.35 mL) |
Studies report administration 45 minutes prior to sexual activity. Maximum 1 dose/24 hours and ≤8 doses/month as per FDA guidance.
Related compounds
Reconstitution Steps
- Cleanse vial tops with alcohol swab.
- Draw up 1.0 mL bacteriostatic water.
- Slowly inject onto the inner wall of the vial.
- Gently swirl until fully dissolved—do not shake.
- Refrigerate at 2–8 °C and protect from light.
Protocol Overview
- PT-141 is a cyclic heptapeptide, a metabolite of Melanotan II without tanning effects.
- FDA-Approved (Vyleesi®, 2019) for hypoactive sexual desire disorder (HSDD).
- Acts centrally in the hypothalamus via MC4R—enhances desire (not just physical response).
- The 5 mg vial yields ~5 full 1 mg doses or ~10 test doses of 0.5 mg.
Dosing Protocol
- Test: 0.5 mg to assess tolerance (mainly nausea).
- Typical: 1.0–1.75 mg subcutaneously, 45 minutes prior to activity.
- FDA Max: 1.75 mg per dose.
- Frequency: ≤1 dose/24h, ≤8 doses/month.
- No cyclical use required—PRN.
- Break between cycles: No strict washout needed due to PRN use. For intensive use, a 2–4 week break may help restore MC4R sensitivity.
Washout & Cycle Restart
When can I restart?
No strict washout needed due to PRN use. For intensive use, a 2–4 week break may help restore MC4R sensitivity.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized powder: refrigerator or room temp, protected from light.
- Reconstituted: 2–8 °C, use within 28 days.
- Do not freeze post-reconstitution.
Important Notes
- Nausea is the most common side effect (~40%)—start with a lower dose.
- Contraindicated in uncontrolled hypertension or known cardiovascular disease.
- Transient skin hyperpigmentation possible—reversible.
- Avoid concurrent use with naltrexone (opposite effect on MC4R).
- This protocol is for educational/research purposes only.
Potential Benefits & Side Effects
Potential Benefits:
- FDA-Approved for HSDD in premenopausal women (Vyleesi®)
- Central Nervous System Action—increases desire via MC4R/dopamine
- Effective in men and women (Erectile Dysfunction studies)
- Independent of vascular health—works where PDE5i fail
- Rapid Onset (~45 min), 6–12 hour duration
- PRN use—not daily
Potential Side Effects:
- Nausea (~40%)—reduced by lower dose & light meal
- Flushing (~20%)
- Headache (mild, transient, ~10%)
- Transient skin hyperpigmentation
- Transient blood pressure increase (~1–3 mmHg)
- Rare: nasal congestion, dizziness
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Transient hypertension
Bremelanotide causes transient blood pressure increase (systolic ~6mmHg). Contraindicated in uncontrolled hypertension.
📄 FDA Label — Vyleesi®References
- FDA Approval — Vyleesi (Bremelanotide) — Simon JA et al. Bremelanotide for HSDD in premenopausal women. Obstet Gynecol. 2019;134(5):899-908.
View Source - RECONNECT Phase III Trial — Kingsberg SA et al. Bremelanotide for HSDD: two RCTs. N Engl J Med. 2019;381(14):1346-1356.
View Source - MC4R Mechanism — Molinoff PB et al. PT-141: a melanocortin agonist for sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102.
View Source - Male Erectile Dysfunction Studies — Diamond LE et al. Subjective sexual response with bremelanotide. J Sex Med. 2006;3(4):628-638.
View Source - Safety & Pharmacology Review — Clayton AH et al. Bremelanotide for female sexual dysfunctions. Expert Opin Pharmacother. 2020;21(8):881-892.
View Source
Recommended Supplements
Maca Root Extract
Ashwagandha (KSM-66)
External Sources & Regulatory Status
Regulatory Approvals
Vyleesi® · HSDD (women) (2019)
FDA approved (Vyleesi®)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →